CanSino: Combined DPT vaccine approved for clinical trials in children aged 4 to 5
2026-11-16 17:54:24
According to CoinMeta, CanSino announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The adsorbed acellular pertussis, diphtheria, and tetanus combined vaccine ( Td5cp ) has been approved for clinical trials in children aged 4 to 5 years old to prevent pertussis, diphtheria, and tetanus. The version of this vaccine for individuals aged 6 and above has been included in the priority review and approval process, and the application for marketing authorization has been accepted. With this approval, the age range for booster immunization with this vaccine is proposed to be extended to 4 to 6 years old, aiming to fill the immunization gap before school entry. Currently, clinical trials for this vaccine are still required, and there is uncertainty regarding the subsequent market launch timeline.
Bullish 0
Bearish 0
Source:Jin10 Data
This content is for market information only and does not constitute investment advice.